<SEC-DOCUMENT>0001104659-25-079244.txt : 20250815
<SEC-HEADER>0001104659-25-079244.hdr.sgml : 20250815
<ACCEPTANCE-DATETIME>20250815161452
ACCESSION NUMBER:		0001104659-25-079244
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250815
DATE AS OF CHANGE:		20250815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LAVA Therapeutics NV
		CENTRAL INDEX KEY:			0001840748
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40241
		FILM NUMBER:		251224797

	BUSINESS ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CM
		BUSINESS PHONE:		31 6 3000 3035

	MAIL ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CM

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LAVA Therapeutics BV
		DATE OF NAME CHANGE:	20210115
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2522230d6_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(RULE 14a-101)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant&ensp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant&ensp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary Proxy Statement </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))&nbsp;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Proxy Statement </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitive Additional Materials </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LAVA Therapeutics N.V. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fee required. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee paid previously with preliminary materials. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.35in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously announced, LAVA Therapeutics N.V.,
a public limited liability company (<I>naamloze vennootschap</I>) organized under the laws of the Netherlands (&ldquo;<U>LAVA</U>&rdquo;),
has entered into a share purchase agreement, dated as of August 3, 2025 (the &ldquo;<U>Purchase Agreement</U>&rdquo;), with XOMA Royalty
Corporation, a Nevada corporation (&ldquo;<U>XOMA</U>&rdquo;). Pursuant to the Purchase Agreement, XOMA has, on August 15, 2025, commenced
a tender offer (the &ldquo;<U>Offer</U>&rdquo;) to purchase all of the issued and outstanding common shares, par value &euro;0.12 per
share (the &ldquo;<U>Shares</U>&rdquo;), in the capital of LAVA for a price per Share of $1.16 (the &ldquo;<U>Base Price Per Share</U>&rdquo;)
plus an additional amount of cash of up to $0.08 per Share (such amount as finally determined in accordance with the Purchase Agreement,
the &ldquo;<U>Additional Price Per Share</U>,&rdquo; and together with the Base Price Per Share, the &ldquo;<U>Cash Amount</U>&rdquo;)
plus one contingent value right (&ldquo;<U>CVR</U>&rdquo;) per Share, which shall represent the right to receive potential payments,
in cash, described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, payable subject to any applicable
tax withholding and without interest (together with the Cash Amount, the &ldquo;<U>Offer Consideration</U>&rdquo;). In connection with
the Offer, XOMA has filed an Offer to Purchase, the related Letter of Transmittal and other relevant documents with respect to the Offer
(the &ldquo;<U>Offer Documents</U>&rdquo;) with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;). LAVA has
concurrently filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 (the &ldquo;<U>Schedule 14D-9</U>&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAVA shareholders should refer to the Offer Documents and the Schedule
14D-9 for more information with respect to the Offer. A proxy statement with respect to the extraordinary general meeting of LAVA shareholders
to be convened pursuant to the Purchase Agreement will be filed at a later date. Shareholders of LAVA are urged to read the proxy statement
and other materials carefully when they become available because they will contain important information that persons should consider
before making any voting decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication is not a recommendation, an
offer to purchase or a solicitation of an offer to sell common shares of LAVA or any other securities. This communication may be deemed
to be solicitation material in respect of the EGM Proposals (defined below). LAVA intends to file with the SEC a definitive proxy statement
in connection with an extraordinary general meeting of shareholders of LAVA, at which the LAVA shareholders will vote on certain proposed
resolutions (the &ldquo;<U>EGM Proposals</U>&rdquo;) in connection with the transactions with XOMA referenced in this communication,
and will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTORS
AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDNG THE EXTRAORDINARY GENERAL MEETING AND THE TENDER OFFER MATERIALS (INCLUDING
THE OFFER TO PURCHASE, A LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9
REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES (INCLUDING
THE TERMS AND CONDITIONS OF THE OFFER) OR MAKING ANY VOTING DECISION FOR THE EXTRAORDINARY GENERAL MEETING.</B></FONT>&nbsp;Investors
and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website
maintained by the SEC at www.sec.gov. Investors and security holders may also obtain, at no charge, the documents filed or furnished to
the SEC by the Company under the &ldquo;SEC Filings&rdquo; subsection of the &ldquo;Financial Information&rdquo; section of the Company&rsquo;s
website at https://ir.lavatherapeutics.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">LAVA, its directors and executive officers and other members of its
management and employees, as well as XOMA and its directors and executive officers, may be deemed to be participants in the solicitation
of proxies from LAVA&rsquo;s shareholders in connection with the EGM Proposals. Information about LAVA&rsquo;s directors and executive
officers and their ownership of LAVA&rsquo;s common shares is set forth in the definitive proxy statement for LAVA&rsquo;s 2025 annual
general meeting of shareholders, which was filed with the SEC on April 28, 2025 and revised on May 27, 2025. Information about XOMA&rsquo;s
directors and executive officers is set forth in the proxy statement for XOMA&rsquo;s 2025 annual meeting of shareholders, which was filed
with the SEC on April 15, 2025. Shareholders may obtain additional information regarding the direct and indirect interests of the participants
in the solicitation of proxies in connection with the EGM Proposals, including the interests of LAVA&rsquo;s directors and executive officers
in the transaction, which may be different than those of LAVA&rsquo;s shareholders generally, by reading the proxy statement and other
relevant documents regarding the transaction which will be filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This communication contains
&ldquo;forward-looking statements,&rdquo; including, but not limited to, statements regarding the Company&rsquo;s beliefs and
expectations and statements about the proposed transaction, including the benefits of the proposed transaction; filings and
approvals relating to the proposed transaction; the expected timing of the completion of the proposed transaction; the potential
payment of proceeds to the Company&rsquo;s shareholders, if any, pursuant to the CVR Agreement; and the ability and timing to
complete the proposed transactions considering the various closing conditions and the consideration to be received by the Company
under the Purchase Agreement. These statements may be identified by their use of forward-looking terminology including, but not
limited to, &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;goal,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;target,&rdquo;
&ldquo;will,&rdquo; and &ldquo;would,&rdquo; and similar words and expressions which are intended to identify forward-looking
statements. Forward-looking statements are neither historical facts nor assurances of future performance and involve risks and
uncertainties that could cause actual results to differ materially from those projected, expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are not limited to: the possibility that various closing
conditions set forth in the Purchase Agreement may not be satisfied or waived, including uncertainties as to the percentage of the
Company&rsquo;s shareholders tendering their shares in the Offer; the possibility that competing offers will be made; the
possibility that the closing conditions might not be met; the risk that the Transactions may not be completed in a timely manner, or
at all, which may adversely affect the Company&rsquo;s business and the price of its ordinary shares; the delay or failure of the
Offer Conditions to be satisfied (or waived), including insufficient ordinary shares of LAVA being tendered in the Offer;
significant costs associated with the Transactions; the risk that any shareholder or other litigation in connection with the
Transactions may result in significant costs of defense, indemnification and liability; the risk that activities related to the CVR
Agreement may not result in any value to the Company&rsquo;s shareholders; the possibility that prior to the completion of the
Transactions, LAVA&rsquo;s or XOMA&rsquo;s business may experience significant disruptions due to transaction-related uncertainty;
the effects of disruption from the Transactions of LAVA&rsquo;s business and the fact that the announcement and pendency of the
Transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors or
business partners; the occurrence of any event, change or other circumstance that could give rise to the termination of the Purchase
Agreement; as well as potential adverse effects on the Company&rsquo;s business condition and results from general economic and
market conditions and overall fluctuations in the United States and international equity markets, including as a result of
inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the
Russian invasion of Ukraine and the conflict in the Middle East; and other risks and uncertainties discussed in the Company&rsquo;s
most recent annual and quarterly reports filed with the SEC as well as in the Company&rsquo;s subsequent filings with the SEC. As a
result of such risks and uncertainties, the Company&rsquo;s actual results may differ materially from any future results,
performance or achievements discussed in or implied by the forward-looking statements contained herein. There can be no assurance
that the Transactions will in fact be consummated. The Company cautions investors not to unduly rely on any forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The forward-looking statements contained in this
communication are made as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements, whether
as a result of future events, new information or otherwise, except as expressly required by law. All forward-looking statements in this
document are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
